The 340B Drug Pricing Program is essential in providing affordable medications to underserved populations, but as it grows, so do the complexities surround compliance. With the program now reaching over $50 billion annually, it’s vital for stakeholders, including manufacturers and 340B organizations, to stay ahead of evolving 340B audit requirements, new legal challenges, and regulatory changes.
Read More: https://340bwell.com/case-studies/navigating-compliance-and-legal-chall…